Preceding Study Toward Establishing Optimal Blood Concentrations of Mycophenolate Mofetil

Preceding Study Toward Establishing Optimal Blood Concentrations of Mycophenolate Mofetil for Pediatric Steroid-Resistant Nephrotic Syndrome and Pediatric Renal Transplantation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031230722

Enrollment

Registered

2024-03-20

Start date

2024-03-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric steroid-resistant nephrotic syndrome Pediatric renal transplant recipients steroid-resistant nephrotic syndrome,kidney transplantation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children with steroid-resistant nephrotic syndrome or pediatric renal transplant recipients who are currently receiving outpatient care or hospitalized at the Pediatric Department of Jichi Medical University , and who have passed at least 7 days after the introduction of mycophenolate mofetil (MMF).

Exclusion criteria

Exclusion criteria: Children who do not meet the selection criteria

Design outcomes

Primary

Measure	Time frame
The predicted area under the curve (AUC 0-12) of MPA during pediatric SRNS (induction of remission, maintenance of remission, refractory cases, relapse, onset of side effects) and pediatric renal transplant treatment (transplant induction, transplant induction rejection, transplant maintenance, transplant maintenance rejection, onset of side effects) based on MPA blood concentrations (before MMF ingestion, 1 hour after ingestion, 2 hours after ingestion, 3 hours after ingestion or 4 hours after ingestion, 6 hours after ingestion).	—

Measure

Time frame

The predicted area under the curve (AUC 0-12) of MPA during pediatric SRNS (induction of remission, maintenance of remission, refractory cases, relapse, onset of side effects) and pediatric renal transplant treatment (transplant induction, transplant induction rejection, transplant maintenance, transplant maintenance rejection, onset of side effects) based on MPA blood concentrations (before MMF ingestion, 1 hour after ingestion, 2 hours after ingestion, 3 hours after ingestion or 4 hours after ingestion, 6 hours after ingestion).

—

Secondary

Measure	Time frame
The correlation between MPA blood concentration and the following factors: side effects, serum albumin levels, serum creatinine levels, cyclosporine blood concentration, and tacrolimus blood concentration.	—

Contacts

Public ContactMarika Ono

Jichi Medical University Hospital

r1715om@jichi.ac.jp+81-285-44-2111

Outcome results